LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood Test Designed for Multiple Tick-borne Diseases

By LabMedica International staff writers
Posted on 27 Feb 2018
Print article
Image: A newly developed blood test detects pathogens carried by ticks such as this hard-bodied tick of the family Ixodidae (Photo courtesy of the CDC).
Image: A newly developed blood test detects pathogens carried by ticks such as this hard-bodied tick of the family Ixodidae (Photo courtesy of the CDC).
A novel blood test for the simultaneous diagnosis of multiple tick-borne diseases has been developed and shown to discriminate antibody responses to eight major tick-borne pathogens present in the United States.

Investigators at Columbia University (New York, NY, USA) demonstrated the ability of the Tick-Borne Disease Serochip (TBD-Serochip) assay to detect and differentiate Anaplasma phagocytophilum, Babesia microti, Borrelia burgdorferi, Borrelia miyamotoi, Ehrlichia chaffeensis, Rickettsia rickettsii, Heartland virus and Powassan virus.

Each assay contained approximately 170,000 12-mer linear peptides that tiled along the protein sequence of the major antigens from each agent with 11 amino acid overlap. This format enabled accurate identification of a wide range of specific immunodominant IgG and IgM epitopes that could then be used to enhance diagnostic accuracy and integrate differential diagnosis into a single assay.

The new test should replace the cumbersome two-test approach currently used to diagnose Lyme disease, the most common TBD. This method, which relies on subjective criteria for the interpretation of results, accurately identifies fewer than 40% of patients with early disease and results in false positives 28% of the time.

To test the performance of the TBD-Serochip, the investigators examined sera from patients with confirmed Lyme disease, babesiosis, anaplasmosis, and Powassan virus disease. They identified a wide range of specific discriminatory epitopes that facilitated accurate diagnosis of each disease. In addition, they also identified previously undiagnosed infections.

"Diagnosing tick-borne illness is a difficult journey for patients, delaying effecting treatment," said senior author Dr. W. Ian Lipkin, professor of epidemiology at Columbia University. "The TBD-Serochip promises to make diagnosis far easier, offering a single, accurate test for eight different TBDs. Early detection of infection enables rapid and appropriate treatment."

The TBD-Serochip test was described in detail in the February 16, 2018, online edition of the journal Nature: Scientific Reports.

Related Links:
Columbia University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more